Identification of Bioactive SNM1A Inhibitors

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• SNM1A is a nuclease essential for repairing DNA interstrand cross-links (ICLs).
• ICLs are induced by certain chemotherapy drugs like cisplatin.
• SNM1A is a selective target for potentiating chemotherapy.

Purpose of the Study:

• To screen for small molecules that inhibit SNM1A nuclease activity.
• To identify compounds that can enhance the efficacy of ICL-based chemotherapy.

Main Methods:

• A fluorescence-based exonuclease assay was used for high-throughput screening.
• A bioactive compound library was screened against SNM1A.
• Orthogonal gel-based assays confirmed SNM1A inhibitors.
• Cytotoxicity assays were performed to assess compound toxicity and potentiation of cisplatin.

Main Results:

• 52 initial hits were identified from the library screen.
• 22 compounds demonstrated dose-dependent inhibition of SNM1A.
• Nine small molecules were confirmed as SNM1A inhibitors with IC50 values in the mid-nanomolar to low micromolar range.
• Three compounds potentiated cisplatin cytotoxicity without exhibiting toxicity themselves.

Conclusions:

• Small molecules inhibiting SNM1A were identified.
• These compounds represent promising leads for developing novel strategies to enhance ICL-based chemotherapy.
• Further optimization could lead to improved cancer treatment outcomes.